Janux Therapeutics Financials
| JANX Stock | USD 45.21 1.18 2.54% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 28.14 | 26.7967 |
|
|
The financial analysis of Janux Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Janux Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Janux | Select Account or Indicator |
Understanding current and past Janux Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Janux Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Janux Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Janux Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Janux Therapeutics. Check Janux Therapeutics' Beneish M Score to see the likelihood of Janux Therapeutics' management manipulating its earnings.
Janux Therapeutics Stock Summary
Janux Therapeutics competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. Janux Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US47103J1051 |
| CUSIP | 47103J105 |
| Location | California; U.S.A |
| Business Address | 10955 Vista Sorrento |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.januxrx.com |
| Phone | 858 751 4493 |
| Currency | USD - US Dollar |
Janux Therapeutics Key Financial Ratios
| Return On Equity | -0.12 | ||||
| Operating Margin | (81.64) % | ||||
| Price To Sales | 186.58 X | ||||
| Revenue | 8.08 M | ||||
| Gross Profit | (44.83 M) |
Janux Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Janux Therapeutics's current stock value. Our valuation model uses many indicators to compare Janux Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Janux Therapeutics competition to find correlations between indicators driving Janux Therapeutics's intrinsic value. More Info.Janux Therapeutics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . At this time, Janux Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Janux Therapeutics' earnings, one of the primary drivers of an investment's value.Janux Therapeutics Systematic Risk
Janux Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Janux Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Janux Therapeutics correlated with the market. If Beta is less than 0 Janux Therapeutics generally moves in the opposite direction as compared to the market. If Janux Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Janux Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Janux Therapeutics is generally in the same direction as the market. If Beta > 1 Janux Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Janux Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Janux Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Janux Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Janux Therapeutics December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Janux Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Janux Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Janux Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Janux Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Janux Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.68 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 15.08 | |||
| Value At Risk | (4.58) | |||
| Potential Upside | 6.87 |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.